This paper is in the following e-collection/theme issue:

Breast Cancer (213) Mobile Health (mhealth) (2982) Patient-Reported Outcome Measures (PROMs) (294) mHealth for Symptom and Disease Monitoring, Chronic Disease Management (1428) Innovations and Technology in Cancer Care (431) Cancer Self-Management (55)

Published on in Vol 10 (2024)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/54178, first published .
Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosimilar Ogivri With Registry Data for Herceptin in the Treatment of Breast Cancer: Prospective Observational Study (OGIPRO) of Electronic Patient-Reported Outcomes

Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosimilar Ogivri With Registry Data for Herceptin in the Treatment of Breast Cancer: Prospective Observational Study (OGIPRO) of Electronic Patient-Reported Outcomes

Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosimilar Ogivri With Registry Data for Herceptin in the Treatment of Breast Cancer: Prospective Observational Study (OGIPRO) of Electronic Patient-Reported Outcomes

Authors of this article:

Andreas Trojan1, 2 Author Orcid Image ;   Sven Roth3 Author Orcid Image ;   Ziad Atassi2 Author Orcid Image ;   Michael Kiessling2 Author Orcid Image ;   Reinhard Zenhaeusern4 Author Orcid Image ;   Yannick Kadvany5 Author Orcid Image ;   Johannes Schumacher6 Author Orcid Image ;   Gerd A Kullak-Ublick1 Author Orcid Image ;   Matti Aapro7 Author Orcid Image ;   Alexandru Eniu8 Author Orcid Image
Article Authors Cited by Tweetations (2) Metrics

Altmetric

Altmetric discovers Social Media mentions. Click the ‘See more details’ link for a full report.

Dimensions

Dimensions discovers Citations. Click the ‘details’ link for a full report.

Metrics Since Publication

Download .csv
Daily | Monthly | Annually